MediWound (MDWD) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Advanced EscharEx’s Phase III VALUE trial and expanded NexoBrid development and manufacturing capacity; NexoBrid sales remain supply-constrained.
Q3 revenue declined year over year as U.S. government development-services revenue fell; higher VALUE investment contributed to increased losses.
A November public offering and warrant exercises added financing, while anticipated 2026 revenue remains exposed to uncertain U.S.-facility funding.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MediWound
- NexoBrid revenue and EscharEx’s chronic-wound pipeline anchor growth targets.MDWD
Company presentation - VALUE results and expanded NexoBrid capacity are the key upcoming milestones.MDWDH.C. Wainwright 28th Annual Global Investment Conference
- VALUE phase III advances, NexoBrid hits record U.S. sales, 2026 guidance reaffirmed.MDWDQ2 2026
- Validated enzymatic therapies drive strong growth, targeting $1B+ peak sales in chronic wounds.MDWDCorporate presentation
- Enzymatic therapies drive strong growth, with robust data and major market expansion ahead.MDWDCorporate presentation
- Q1 revenue fell but margin improved; BARDA and NexoBrid drive strong H2 2026 outlook.MDWDQ1 2026
- 2025 revenue fell to $17M, but gross margin and cash reserves improved.MDWDQ4 2025
- Q3 revenue up 23% YoY, net loss narrowed, $30M equity raised, and EscharEx peak sales at $831M.MDWDQ3 2025
- Q1 revenue was $4M, gross margin rose to 19%, and NexoBrid U.S. sales reached record highs.MDWDQ1 2025